Efficacy and safety of a 0/1-h high-sensitivity cardiac troponin I (hs-cTnI) protocol to rule out acute coronary syndrome over a one-year period
Kelly Perryman , David Winchester , Michael Massoomi , Elizabeth Warren , Linda Morris , Stacy Beal , Nila Radhakrishnan , Umar Ghaffar , Jacob Sammon , Justin Raman , Marsha Lewis , David Crabb , Liam Holtzman , Brandon Allen
Vessel Plus ›› 2023, Vol. 7 ›› Issue (1) : 7
Efficacy and safety of a 0/1-h high-sensitivity cardiac troponin I (hs-cTnI) protocol to rule out acute coronary syndrome over a one-year period
Aim: Evaluate the diagnostic and prognostic performance of the ESC 0/1H Algorithm and its utility in safely discharging patients with suspected Acute Coronary Syndrome (ACS) in the Emergency Department.
Methods: This analysis is a retrospective cohort study of 3,156 patients presenting to an academic medical center emergency department (ED) between May 20, 2019 and May 31, 2020. After completing the Beckman Coulter Access High Sensitivity Troponin I (hs-TnI) assay per current institution protocol (T0, T1H, T3H), patients identified to have symptoms concerning ACS were retrospectively analyzed using the ESC 0/1H Algorithm to assess the safety and efficacy of a rule-out algorithm for early discharge.
Results: The negative predictive value (NPV) of the protocol (T0 < 6 pg/mL; or females with T0 ≤ 15 pg/mL and
Conclusion: The protocol was found to have a NPV greater than 99% and a negative likelihood ratio of 0.08, suggesting it is safe to use for patients presenting to the ED with ACS symptoms no matter the time of symptom onset.
High sensitivity troponin / emergency medicine / myocardial infarction
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
High-sensitivity* cardiac troponin I and T assay analytical characteristics designated by manufacturer IFCC committee on clinical applications of cardiac bio-markers (C-CB) V062019. Available from: https://ifcc.org/ifcc-education-division/emd-committees/committee-on-clinical-applications-of-cardiac-bio-markers-c-cb/biomarkers-reference-tables/ [Last accessed on 24 March 2023] |
| [28] |
CDRH. 510(k) substantial equivalence determination decision memorandum assay only template. Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/K170200.pdf [Last accessed on 24 March 2023] |
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
/
| 〈 |
|
〉 |